Benralizumab Fasenra®
The official Q-BEN record describes benralizumab as a humanised IgG1κ monoclonal antibody that binds the alpha chain of the interleukin-5 receptor. The SHIKARI® Benralizumab portfolio supports quantitative measurement of benralizumab and qualitative detection of specific anti-benralizumab antibodies.
Why Benralizumab is relevant to biological-drug monitoring research
Benralizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Benralizumab is an afucosylated humanised IgG1 monoclonal antibody targeting IL-5 receptor-α. Its Fc design promotes antibody-dependent cellular cytotoxicity and depletion of eosinophils and basophils. Source ↗
Approved Indications
EMA-authorised uses include add-on treatment of severe eosinophilic asthma and treatment of relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) in defined patients. EMA source ↗
Observed Trough Exposure
Clinical pharmacology data under the 30 mg regimen every 8 weeks after the initial loading phase show low but measurable trough exposure:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two complementary research assays
Enzyme immunoassay for the quantitative determination of benralizumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Enzyme immunoassay for the qualitative determination of specific antibodies to benralizumab in human serum and plasma, reported as a positive or negative result.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-BEN | BEN-FD-FAS | Drug-Level Kit | Benralizumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATBE | BEN-QLS-FAS | Qualitative ADA Kit | Antibodies to benralizumab | ELISA | 96 | 2–8°C |
* Store at +4°C and refer to the current protocol supplied with the kit. Both official records list human species reactivity. Q-BEN spike recovery is 85–115%. Specifications were verified against the exact official product records.
Which kit fits your research question?
Choose the drug-concentration assay or the qualitative anti-drug-antibody assay according to the required analytical output.
Benralizumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Benralizumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.